Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy

Neurology

Volumn 80, Issue 20, 2013, Pages 1862-1866

  Horton, Lindsay ^a   Conger, Amy ^a   Conger, Darrel ^a   Remington, Gina ^a   Frohman, Teresa ^a   Frohman, Elliot ^a   Greenberg, Benjamin ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; PLACEBO; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINAL NERVE FIBER LAYER THICKNESS; VISUAL ACUITY;

4-AMINOPYRIDINE; ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASES; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISION, OCULAR; YOUNG ADULT;

EID: 84879105482     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182929fd5     Document Type: Article

References (20)

1. Balcer LJ. Clinical practice: optic neuritis. N Engl J Med 2006;354:1273-1280.
2. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005;4:111-121.
3. Ashworth B, Aspinall PA, Mitchell JD. Visual function in multiple sclerosis. Doc Ophthalmol 1989;73:209-224.
4. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005;64:992-995.
5. Balcer LJ, Baier ML, Pelak VS, et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler 2000;6:163-171.
6. Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology 2010;74(suppl 3):S16-S23.
7. Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis: results from the Optic Neuritis Treatment Trial. J Neuroophthalmol 1997;17:18-23.
8. Fleishman JA, Beck RW, Linares OA, Klein JW. Deficits in visual function after resolution of optic neuritis. Ophthalmology 1987;94:1029-1035.
9. Kupersmith MJ, Nelson JI, Seiple WH, Carr RE, Weiss PA. The 20/20 eye in multiple sclerosis. Neurology 1983;33:1015-1020.
10. Davis SL, Wilson TE, White AT, Frohman EM. Thermoregulation in multiple sclerosis. J Appl Physiol 2010;109:1531-1537.
11. Frohman TC, Davis SL, Frohman EM. Modeling the mechanisms of Uhthoff s phenomenon in MS patients with internuclear ophthalmoparesis. Ann NY Acad Sci 2011;1233:313-319.
12. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006;113:324-332.
13. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005;58:383-391.
14. Sherratt RM, Bostock H, Sears TA. Effects of4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature. 1980;283:570-572.
15. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-192.
16. Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, doubleblind, concentration-controlled, crossover trial. Neurology 1994;44:1054-1059.
17. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-362.
18. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51:292-296.
19. Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-77.
20. Goodman AD, Brown TR, Krupp LB, et al. Sustainedrelease oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732-738.